Vol. 65 No. 3 (2019), REVIEWS

Vol. 65 No. 3 (2019)

POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW)

REVIEWS

https://doi.org/10.37469/0507-3758-2019-65-3-330-336

Published 01.03.2019

Irina Gribkova⁺⁻
I. Ishmatova⁺⁻
Mariya Davydovskaya⁺⁻
K. Kokushkin⁺⁻

Irina Gribkova

SBI «CTHTA SRC MDH»

I. Ishmatova

Federal State Budget Institution «N.N.Petrov's National Medical Research Center of Oncology» Ministry of Healthcare of the Russian Federation

Mariya Davydovskaya

SBI «CTHTA SRC MDH», Neurosurgery and Medical Genetics of Pirogov Russian National Research Medical University

K. Kokushkin

SBI «CTHTA SRC MDH»

##article.numberofdownloads## 76

##article.numberofviews## 90

PDF (Русский)

Keywords

LITERATURE REVIEW
MYELOFIBROSIS
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
RUXOLITINIB

How to Cite

Gribkova, I., Ishmatova, I., Davydovskaya, M., & Kokushkin, K. (2019). POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW). Voprosy Onkologii, 65(3), 330–336. https://doi.org/10.37469/0507-3758-2019-65-3-330-336

Abstract

The aim of the study was to systematize and summarize the current available data on ruxolitinib use in patients with myelofibrosis (MF) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) to improve its results. The review includes data from foreign and domestic articles found in the PubMed and elibrary.ru databases describing the results of the use of ruxolitinib in patients with MF prior to allo-HSCT, including clinical cases, original scientific studies and reviews. It is reported that ruxolitinib therapy is safe, reduces mortality in the early post-transplantation period, reduces the incidence of acute and chronic graft-versus-host disease, and decreases the frequency of relapses. Clinical improvement with ruxolitinib therapy prior to allo-HSCT can be considered a prognostically favorable factor.

https://doi.org/10.37469/0507-3758-2019-65-3-330-336

##article.numberofdownloads## 76

##article.numberofviews## 90

PDF (Русский)

References

Teo S, Tiedt R, Passweg JR.et al. A Gain-of-Function Mutation of JAK2. NEJM. 2005;352(17): 1779-1790.

Plosker GL. Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis. Drugs. 2015;75:297-308. DOI: 10.1007/s40265-015-0351-8

Verstovsek S. Changing myelofibrosis’s natural course at last. Blood. 2014;123(12):1776-7.

Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26): 4399-413.

Santos FP, Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 2012;12(9):1098-109.

Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010;3(3):323- 37.

Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82.

Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405.

Клименко С.В., Мищенюк О.Ю. Эффективность и безопасность руксолитиниба при лечении миелофиброза по данным исследований COMFORT I и COMFORT II. Здоровье Украины. Онкогематология. 2015; 21-22.

Verstovsek S, Mesa RA, Gotlib J, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New Eng J Med. 2012: March 1;366:799-807.

Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New Eng J Med. 2012: March 1;3бб:787-98.

Bradley EC, Erickson-Viitanen S, Vaddi K et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. NEJM. 2010;362(15): 1117-1127.

Verstovsek S, Mesa RA, Gotlib J et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4): 479-488.

Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17): 2635-42.

Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COM-FORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047-53.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8): 1701-7.

Harrison CN, Bennett M. Orphan drugs for myelofibrosis. Expert Opin Orphan Drugs. 2014;2(4):391-405.

Mascarenhas J. Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol. 2014;27(2):197-208.

Stubig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736-8.

Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179-84.

Qureshi MR, MacLean C, McMullin MF, et al. Management of myelofibrosis: a survey of current practice in the United Kingdom. J Clin Pathol. 2012;65(12):1124-7.

Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J. 2012;2(3):e59.

Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; 120: 1367-1379.

Барабанщикова М.В., Морозова Е.В., Байков В.В. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при миелофиброзе. Клиническая онкогематология. 2016;9(3):279-86. DOI: 10.21320/2500-2139-2016-9-3-279-286

Akpek G, Pasquini MC, Logan B. et al. Effects of spleen status on early outcomes after hematopoietic cell trans plantation. Bone Marrow Transplant. 2013;48(6): 825831.

Ballen KK, Shrestha S., Sobocinski KA. et al. Outcome of transplantation for Myelofibrosis. Biol. Blood Marrow Transplant. 2010;16(3): 358-367.

Kroger N., Holler E., Kobbe G. et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26): 5264-5270.

Rondelli D., Goldberg JD, Isola L. et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124(7): 1183-1191.

Bacigalupo A., Soraru M., Dominietto A., Pozzi S., Geroldi S., Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458-463.

Matsubara E., Yamanouchi J., Kitazawa R., Azuma T., Fujiwara H., Hato T., Yasukawa M. Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis. Case Rep Hematol. 2016; 2016: 8751329.

Robin M., Zine M., Chevret S., Meignin V., Munoz-Bongrand N., Moatti H., Xhaard A., Sicre de Fontbrune F., Peffault de Latour R., Sarfati E., Socie G. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(6): 958-64.

Kadir S., Christopeit M., Wulf G., Wagner E., Bornhauser M., Schroeder T., Crysandt M., Mayer K., Jonas J., Stelljes M., Badbaran A., Ayuketang Ayuk F., Triviai I., Wolf D., Wolschke C., Kroger N. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J. Haematol. 2018 Sep;101(3):305-317. Epub 2018 Jul 4. DOI: 10.1111/ejh.13099

Ballinger TJ, Savani BN, Gupta V., Kroger N., Mohty M. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. Eur J. Haematol. 2015; 94(2):115-119.

Shanavas M., Messner HA, Atenafu EG, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant 49: 1162-1169, 2014.

Spoeri S., Mathew NR, Bscheider M., et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123: 3832- 3842, 2014.

Lavi N., Rowe JM, Zuckerman T. Allogeneic stemcell transplantation for myelofibrosis. Curr opin Hematol. 2017 Nov;24(6):475-480.

Shanavas M., Popat U., Michaelis L.C. et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016; 22(3): 432-40.

Robin M., Francois S., Huynh A. et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the Sfgmtc. Blood 2013; 122: 306.

Hanif A., Hari P.N., Atallah E. et al. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016 Apr;51(4):617-8.

Kroger N., Shahnaz Syed Abd Kadir S., Zabelina T., Badbaran A., Christopeit M., Ayuk F., Wolschke C. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 May 22. pii: S1083-8791(18)30295-7. DOI: 10.1016/j.bbmt.2018.05.023

Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143: 1478-1479.

Goldberg RA, Reichel E., Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N. Engl J. Med. 2013;369: 681-683.

Colomba C., Rubino R., Siracusa L., et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012;5: 552.

Heine A., Held SA, Daecke SN, Wallner S. et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013; 122(7): 1192-202.

Heine A., Brossart P., Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013; 122(23): 3843-4.

Chatterjee B., Rqieh U., Greaves P., Piras D., Firth J., Saja K. Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis. Br J. Haematol. 2015;169: 307.

Sakoda T., Kanamitsu X. Mori Y. et al. Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation. Intern Med. 2017 Sep 15;56(18):2481-2485.

Parampalli Yajnanarayana S., Stubig T., Cornez I., et al. JAK1/2 inhibition impairs T. cell function in vitro and in patients with myeloproliferative neoplasms. Br J. Haematol. 2015;169:824-833.

Zeiser R., Burchert A., Lengerke C. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10): 2062-2068.

Барабанщикова М.В., Морозова Е.В., Власова Ю.Ю., Байков В.В., Зубаровская Л.С., Афанасьев Б.В. Применение ингибитора JAK1 и JAK2 руксолитиниба в качестве пред- и пост-трансплантационной терапии пациентов с миелофиброзом. Ученые записки СПбГМУ им. акад. И. П. Павлова. 2016; 23(1): 43-46.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Irina Gribkova, Vera Krysanova, Aleksandr Zavyalov, ECONOMIC BURDEN OF SKIN MELANOMA (LITERATURE REVIEW) , Voprosy onkologii : Vol. 66 No. 3 (2020)
Irina Gribkova, Aleksandr Zavyalov, Chimeric antigen receptor T‑cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges , Voprosy onkologii : Vol. 67 No. 3 (2021)
Irina Gribkova, Aleksander Zavyalov, Sources of NK Cells for CAR-Technologies , Voprosy onkologii : Vol. 69 No. 4 (2023)
Larisa Filatova, Yevgeniya Kharchenko, Sergey Alekseev, Ilya Zyuzgin, Anna Artemeva, Margarita Motalkina, Tatyana Semiglazova, I. Ishmatova, P. Shilo, PROSPECTS FOR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE FIRST LINE OF THERAPY FOR AGGRESSIVE NON-HODGKIN’S LYMPHOMAS , Voprosy onkologii : Vol. 63 No. 2 (2017)
Sergey Alekseev, A. Subora, P. Shilo, I. Ishmatova, Tatyana Semiglazova, Larisa Filatova, Svetlana Kuleva, Yuliya Oleynik, Yuliya Chudinovskikh, Yevgeniya Kharchenko, Margarita Motalkina, Ilya Zyuzgin, S. Shalaev, ANALYSIS OF UNFAVORABLE PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL HEMOPOIETIC STEM CELLS TRANSPLANTATION FOR RELAPSES AND RESISTANT FORMS OF HODGKIN''S LYMPHOMA , Voprosy onkologii : Vol. 64 No. 3 (2018)
Irina Gribkova , Aleksander Zavyalov, Exploring the potential of rivaroxaban in children with cancer: advantages over standard anticoagulants , Voprosy onkologii : Vol. 69 No. 3 (2023)